Clinical Trial Update: Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abiraterone acetate without exogenous glucocorticoids in men with castration-resistant prostate cancer; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-11-08